Anakinra Prophylaxis during BCMA-Directed CAR-T Therapy: A Two-Center Analysis of Toxicity and Outcomes

Key Points

• Anakinra prophylaxis reduces toxicity associated with bcma-directed car-t therapy in patients, improving their overall outcomes.
• Key findings indicate that the use of anakinra led to a significant decrease in severe adverse effects, enhancing treatment tolerability.
• Analytical approach involved a two-center assessment, monitoring the efficacy and safety profiles during car-t therapy.
• Findings highlight the need for further exploration of anakinra in preventing toxicities in broader clinical settings.